VIPLUSMA
Novartis AG
Application Filed: 2023-11-20
Trademark Application Details
NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER
| Research |
OneLook
Acronym Finder
|
| Serial Number | 79386354 |
| Mark Drawing Code | 4000: Illustration: Drawing with word(s)/letter(s)/number(s) in Block form |
Timeline
| 2023-11-20 | Application Filed |
| 2023-12-28 | Location: INITIAL REVIEW/SERIALIZATION BRANCH(MAILROOM) |
| 2023-12-28 | Status: Live/Pending |
| 2024-01-17 | Transaction Date |
Trademark Applicants & Owners
| Owner: |  Novartis AG |
| Address | CH-4002 Basel CH |
| Legal Entity Type | Corporation |
| Legal Entity State | CH |
Documents
Click the blue "Refresh" button to load certificates, specimines, application, and other documents.
Attorney of Record
Good, Services, and Codes
| International Codes: | 5 |
| U.S. Codes: | 005,006,018,044,046,051,052 |
| Type Code | Type |
|---|---|
| GS0051 | Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma |
| GS0051 | Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma |
Trademark Filing History
| Description | Date | Event Coding |
|---|---|---|
| SN ASSIGNED FOR SECT 66A APPL FROM IB | 2023-12-28 | 1 REPR M: |
| LIMITATION FROM ORIGINAL APPLICATION ENTERED | 2024-01-03 | 2 LIMI I:Incoming Correspondence |
| NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | 2024-01-17 | 3 NWOS I:Incoming Correspondence |
| APPLICATION FILING RECEIPT MAILED | 2024-01-23 | 4 MAFR O:Outgoing Correspondence |
| TEAS CHANGE OF OWNER ADDRESS RECEIVED | 2024-03-08 | 5 COAR I:Incoming Correspondence |
| APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | 2024-03-08 | 6 CHAN I:Incoming Correspondence |
| TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | 2024-03-08 | 7 REAP I:Incoming Correspondence |
| ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | 2024-03-08 | 8 ARAA I:Incoming Correspondence |
| TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | 2024-03-08 | 9 ECDR I:Incoming Correspondence |
| TEAS CHANGE OF CORRESPONDENCE RECEIVED | 2024-03-08 | 10 TCCA I:Incoming Correspondence |
| ASSIGNED TO EXAMINER | 2024-03-15 | 11 DOCK D:Assigned to Examiner |
| APPROVED FOR PUB - PRINCIPAL REGISTER | 2024-03-25 | 12 CNSA O:Outgoing Correspondence |
| NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | 2024-04-10 | 13 NONP E:E-Mail |
| PUBLISHED FOR OPPOSITION | 2024-04-30 | 14 PUBO A:Allowance for Publication |
| OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | 2024-04-30 | 15 NPUB E:E-Mail |
| REGISTERED-PRINCIPAL REGISTER | 2024-07-16 | 16 R.PR A:Allowance for Publication |
| REGISTERED-PRINCIPAL REGISTER | 2024-07-16 | 17 R.PR A:Allowance for Publication |
| NOTICE OF REGISTRATION CONFIRMATION EMAILED | 2024-07-16 | 18 NRCC E:E-Mail |
| FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | 2024-08-15 | 19 FICR P: |
Similar Marks
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
 VIPLUSMA 88758608 not registered Live/Pending |
ENDOCYTE, INC. 2020-01-14 |
 VIPLUSMA 79386354 not registered Live/Pending |
Novartis AG 2023-11-20 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 